Business Daily Media

Business Marketing

.

Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies

  • Written by ACN Newswire - Press Releases

Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies

TOKYO, Apr 23, 2021 - (JCN Newswire) - Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Gilead submitted an application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis. Filgotinib is a new oral...

Popular

6 Waste Disposal Practices To Maintain A Clean Workplace

Maintaining a clean workplace is crucial for creating a healthy and productive environment for employees. Proper waste disposal practices play a significant role in achieving this goal, as they help prevent the accumulation of...

What Are the Pros and Cons of Turning Your Fun Hobby Into a Business?

They say that if you love what you do, you’ll never work a day in your life. The COVID-19 pandemic left many people looking for ways to supplement lost income or support themselves entirely as businesses closed their doors. Th...

Ways to make your workplace more inclusive in 2024

Creating more inclusive workplaces in Australia for people with disabilities is essential for fostering diversity, equity, and positive working environments.  Following the Disability Royal Commission last year, the recomme...

Virtual Office
Tomorrow Business Growth